San Diego, CA — November 5, 2025 — Leads & Copy — Quantumzyme Corp. (OTC: QTZM) has announced the publication of research on sustainable ibuprofen synthesis in RSC Sustainability. The peer-reviewed article, titled “In silico enzyme engineering of aldehyde dehydrogenase for eco-friendly ibuprofen synthesis” (DOI: 10.1039/D5SU00073D), validates Quantumzyme’s enzymatic process for ibuprofen production, using digital biology and advanced enzyme design. Experimental data confirms the feasibility of Quantumzyme’s computationally engineered enzymes, aligning with global green chemistry goals and demonstrating potential for large-scale Active Pharmaceutical Ingredient (API) manufacturing with a reduced environmental footprint.
Naveen Kulkarni, CEO of Quantumzyme Corp., stated the publication validates their vision to transform pharmaceutical manufacturing through sustainable innovation. The company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency.
Naveen Kulkarni, Chief Executive Officer, Quantumzyme Corp., Phone: +1 (858) 203-0312, Email:info@quantumzymecorp.com
Source: Quantumzyme Corp.
